// Stay up to date

Newsroom

Follow our progress in developing products that have the potential to transform the future of cancer treatment

eTheRNA groups team members who are all passionate about mRNA technology and who wish to contribute to the development of truly innovative immunotherapies that can help millions of patients by combatting their disease.

Scroll down for our most recent publications

News Archive

Archive 2020
Archive 2019
Archive 2018
Archive 2017
Archive 2016
// 16 June 2020

eTheRNA raises EUR 34 million in Series B financing to accelerate multiple mRNA therapeutic development programs through to clinical proof of concept

  • Advancing oncology and infectious diseases pipeline, including new SARS-CoV-2 program
  • Proprietary mRNA TriMix technology provides unprecedented immune responses
  • Ongoing clinical trials in metastatic melanoma and breast cancer
  • Proprietary LNP platform for intravenous delivery to enter clinical development in HPV-positive cancer
  • Enlarged international investor syndicate includes a new corporate investor

Niel (Belgium) 

eTheRNA immunotherapies NV (‘eTheRNA’ or ‘The Company’), a clinical-stage company developing immunotherapies from its proprietary mRNA TriMix platform for the treatment of cancer and infectious diseases, today announced that it has successfully raised Euro 34 million in a Series B equity financing round. All existing investors – LSP (the Netherlands), PMV (Belgium), Boehringer Ingelheim Venture Fund (Germany), Fund+ (Belgium) and Omega Funds (USA) – are participating in the round. They are joined by Grand Decade, a BVI subsidiary owned by China Grand Pharmaceutical and Healthcare Holdings Ltd (‘GP(HK)’; HKSE Stock code 00512), BNP Paribas Fortis Private Equity (Belgium), Yijing Capital (China) and Novalis LifeSciences LLC (USA). GP(HK) and eTheRNA have also agreed outline terms for a possible exclusive strategic partnership for mRNA manufacturing, independent research and development, production and commercialization in Greater China.

// 22 April 2020

Frame Therapeutics and eTheRNA immunotherapies NV open a new research collaboration to develop mRNA cancer vaccines against immunogenic neoantigens

Amsterdam (Netherlands) – Niel (Belgium) 

Frame Therapeutics, a new biotechnology company focused on the development of neoantigen-based cancer vaccines, today announced that they have forged a research collaboration with eTheRNA immunotherapies NV, a clinical-stage company developing vaccines and immunotherapies from its proprietary mRNA TriMix platform.

The collaboration aims to develop a new generation of off-the-shelf neoantigen cancer vaccines by combining each company’s immunotherapy expertise and unique technologies. Frame Therapeutics will contribute the discovery and development of the highly immunogenic frameshift neoantigens that are only expressed in specific tumor types and thus offer a new level of patient and tumor specificity. eTheRNA will apply its vaccination technology platform to elicit anti-tumor T-cell responses based by employing its clinically validated TriMix mRNA platform.

// 24 MARCH 2020

eTheRNA Launches an International Consortium and Starts Development of Cross-strain Protective CoV-2 mRNA Vaccine for High Risk Populations

Niel (Belgium) 

eTheRNA immunotherapies NV (Niel, Belgium) announces that that a consortium has been formed with North American and European partners to develop a novel mRNA vaccine against CoV-2 and preclinical development has started. Chinese partners may be added in the consortium in due course.

Administered intranasally, the proposed vaccine is intended primarily for high risk populations such as healthcare workers and families of confirmed cases. It is also designed to be protective against future variations of the virus by targeting conserved epitopes from the whole CoV-2 genome. eTheRNA and its partners EpiVax, Nexelis, REPROCELL and CEV* have extensive experience in the mRNA vaccine field and this will help accelerate progress towards clinical trials with patient enrolment expected in early 2021.

// 1 June 2019

Safety and immune stimulation data from an intranodal delivery of TriMix mRNA, in the adjuvant melanoma study E011-MEL

Niel (Belgium) 

eTheRNA immunotherapies NV (Niel, Belgium) announces that Dr. Ana Arance, Medical Oncologist at Hospital Clinic de Barcelona, will present safety and immune response data from the E011-MEL study at the ASCO (American Society of Clinical Oncology) Annual Meeting during the poster session “Developmental Immunotherapy and Tumor Immunobiology” on 01 June 2019. The study E011-MEL investigated the safety and immunogenicity of a mRNA-based immunotherapy ECI-006. ECI-006 is a combination of mRNAs encoding for the dendritic cell maturation triple mRNA TriMix together with mRNA coding for5 tumor-associated antigens, which aims to elicit an immune response against the tumor. Since the patients had been radically operated on, there was no expected, immediate clinical activity read-out.

The primary goal of the study was to study whether the injection of ECI-006 into inguinal or axillary lymph nodes was tolerable and clinically feasible. The intranodal injections were performed in the clinic under ultrasound guidance without anesthesia. There were two treatment arms, each of 10 patients. One group received a dose of 600 µg and the other a dose of 1800 µg per injection. The study was performed in centres in Belgium and Spain.

Galileilaan 19, 2845 Niel, Belgium

Our Address

Our Mailbox

+32 3 369 17 40

Our Phone

© 2020 Etherna | Studio Hanswijk